CYABRA, INC. (CYAB): Unregistered Sales of Equity Securities
CYABRA, INC. (CYAB) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed, on July 9, 2026, Cyabra, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with Alpha Capital Anstalt (the “Holder”) that holds the outstanding Series C Convertible Prefer
How this was made
The 30-second read
Why it matters
The corporate actions increase share count and introduce new warrant instruments, which may affect liquidity and valuation.
Market read
Primary disclosure of a material corporate restructuring for a micro‑cap, with potential dilution impact on the stock.
What to watch
Potential future financing needs and the impact of anti‑dilution protection removal on existing investors.
Background
CYABRA filed an 8‑K detailing unregistered equity sales, warrant issuances, and conversion of preferred shares following shareholder approval.
Ticker impact
SEC Form 8‑K reports CYABRA's exchange and conversion agreements, issuing pre‑funded and common warrants and cancelling Series C preferred shares.
Potential short‑term price decline due to dilution; long‑term upside if warrants are exercised at favorable prices.
First‑report filing details sizable $10.6M preferred‑share exchange and issuance of over 24M warrants, a material corporate action for a micro‑cap.
Market effects
May affect other micro‑cap biotech/tech firms using similar preferred‑share conversions.
Limited to U.S. over‑the‑counter micro‑cap market.
Low global relevance.
Counterpoint
If the warrants are exercised at low prices, the dilution could be offset by cash inflow, supporting the stock.
Key entities
- companyCYABRA, INC.
Issuer of the securities and subject of the 8‑K filing.
- investorAlpha Capital Anstalt
Holder of Series C preferred shares exchanged for common stock and warrants.
